ATE74512T1 - Pharmazeutische zusammensetzungen von rekombinanten interleukin-2 und herstellungsverfahren. - Google Patents

Pharmazeutische zusammensetzungen von rekombinanten interleukin-2 und herstellungsverfahren.

Info

Publication number
ATE74512T1
ATE74512T1 AT87115694T AT87115694T ATE74512T1 AT E74512 T1 ATE74512 T1 AT E74512T1 AT 87115694 T AT87115694 T AT 87115694T AT 87115694 T AT87115694 T AT 87115694T AT E74512 T1 ATE74512 T1 AT E74512T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
recombinant interleukin
manufacture
solubilizer
stabilizers
Prior art date
Application number
AT87115694T
Other languages
English (en)
Inventor
Ze Ev Shaked
Tracy Stewart
James William Thomson
Pamela Hirtzer
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Corp filed Critical Cetus Corp
Application granted granted Critical
Publication of ATE74512T1 publication Critical patent/ATE74512T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT87115694T 1986-10-27 1987-10-26 Pharmazeutische zusammensetzungen von rekombinanten interleukin-2 und herstellungsverfahren. ATE74512T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92338386A 1986-10-27 1986-10-27
EP87115694A EP0268110B1 (de) 1986-10-27 1987-10-26 Pharmazeutische Zusammensetzungen von rekombinanten Interleukin-2 und Herstellungsverfahren

Publications (1)

Publication Number Publication Date
ATE74512T1 true ATE74512T1 (de) 1992-04-15

Family

ID=25448603

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87115694T ATE74512T1 (de) 1986-10-27 1987-10-26 Pharmazeutische zusammensetzungen von rekombinanten interleukin-2 und herstellungsverfahren.

Country Status (9)

Country Link
EP (1) EP0268110B1 (de)
JP (1) JPS63122628A (de)
AT (1) ATE74512T1 (de)
AU (1) AU614066B2 (de)
CA (1) CA1292686C (de)
DE (1) DE3778122D1 (de)
ES (1) ES2036558T3 (de)
GR (1) GR3004479T3 (de)
IE (1) IE60890B1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
US4931543A (en) * 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2
US7307166B1 (en) 1987-10-28 2007-12-11 Wellstat Therapeutics Corporation Oxpurine nucleosides and their congeners, and acyl, derivatives thereof, for improvement of hematopoiesis
WO1990006127A1 (en) * 1988-12-06 1990-06-14 Otsuka Pharmaceutical Co., Ltd. STABILIZED COMPOSITION OF INTERLEUKIN-1$g(b)
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
JPH0791318B2 (ja) * 1989-09-21 1995-10-04 三井東圧化学株式会社 蛋白質水溶液、蛋白質水溶液の濃度増大方法および蛋白質製剤
US5830452A (en) * 1990-11-20 1998-11-03 Chiron Corporation Method for enhancing the anti-tumor therapeutic index of interleukin-2
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US20030171292A1 (en) 1992-06-01 2003-09-11 Creasey Abla A. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
DK0627924T3 (da) * 1992-10-02 2001-04-30 Genetics Inst Sammensætning, der omfatter koagulationsfaktor VIII formulering, fremgangsmåde til dens fremstilling og anvendelse af et overfladeaktivt middel som stabilisator
AU687763B2 (en) * 1992-10-20 1998-03-05 Central Laboratory Of The Netherlands Red Cross Blood Transfusion Service Interleukin-6 receptor antagonists
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
MXPA04003547A (es) 2001-10-15 2004-07-22 Chiron Corp Tratamiento de sepsis mediante administracion de dosis bajas de inhibidor de via factor de tejido.
PT1682177E (pt) 2003-11-04 2010-11-29 Xoma Technology Lt Utilização de anticorpos antagonistas anti-cd40 para o tratamento da leucemia linfocítica crónica
WO2005044855A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
CA2544368C (en) 2003-11-04 2014-04-01 Chiron Corporation Methods of therapy for b cell-related cancers
PT1682178E (pt) 2003-11-04 2010-10-21 Novartis Vaccines & Diagnostic Métodos de terapêutica para cancros que expressam o antigénio cd40
CA2544852A1 (en) 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
GB0404586D0 (en) * 2004-03-01 2004-04-07 Britannia Pharmaceuticals Ltd Improvements in or relating to organic materials
KR100624013B1 (ko) 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
JP5518608B2 (ja) * 2010-07-09 2014-06-11 ロート製薬株式会社 粘膜適用液状組成物
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
WO2012072088A1 (en) 2010-12-02 2012-06-07 Bionor Immuno As Peptide scaffold design
EA034031B1 (ru) 2011-01-06 2019-12-20 Бионор Иммуно Ас Димерный пептид для индуцирования иммунного ответа против hiv и его применение
DE102012101864A1 (de) * 2012-03-06 2013-09-12 Gramme-Revit Gmbh Mittel zur Behandlung von Allergien und anderen Erkrankungen
US10501499B2 (en) 2012-06-06 2019-12-10 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
UA105278C2 (ru) 2012-09-06 2014-04-25 Інститут Біології Клітини Нан України Способ получения каталитически активных антител (абзимов) с сиалидазной активностью
EP3718467A1 (de) 2013-04-23 2020-10-07 Cedars-Sinai Medical Center Systeme und verfahren zur gleichzeitigen aufzeichnung eines bildes im sichtbaren licht und infrarotlicht aus fluorophoren
CA2935404A1 (en) 2014-01-17 2015-07-23 Cedars-Sinai Medical Center Receptor targeting constructs and uses thereof
CN106794175B (zh) 2014-06-12 2020-06-09 西达-赛奈医疗中心 用于治疗癌症的组合物
CN107072951A (zh) 2014-07-22 2017-08-18 雷莫内克斯生物制药有限公司 用于递送生物活性物质或蛋白质的组合物及其用途
WO2016073647A2 (en) 2014-11-04 2016-05-12 University Of Southern California COMPOSITIONS AND METHODS FOR TREATING HIF-1alpha OVER-EXPRESSING CANCERS
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
EP3292139B1 (de) 2015-05-05 2020-10-28 The Regents of The University of California H3.3-ctl-peptide und verwendungen davon
US11567078B2 (en) 2015-08-31 2023-01-31 Cedars-Sinai Medical Center Blood cell biomarker for late onset Alzheimer's disease
KR20180103817A (ko) 2016-02-09 2018-09-19 오토텔릭 엘엘씨 암을 치료하기 위한 조성물과 방법
KR20180103816A (ko) 2016-02-09 2018-09-19 오토텔릭 엘엘씨 췌장암을 치료하기 위한 조성물과 방법
JP6883354B2 (ja) 2017-02-06 2021-06-09 レモネックス インコーポレイテッドＬｅｍｏｎｅｘ Ｉｎｃ． 生理活性物質送達体
WO2018143787A1 (ko) 2017-02-06 2018-08-09 주식회사 레모넥스 생리활성물질 전달체
EP3658139A4 (de) 2017-07-25 2021-04-07 Cedars-Sinai Medical Center Verfahren zur behandlung von lebererkrankungen
KR102152348B1 (ko) 2017-09-05 2020-09-08 주식회사 레모넥스 세포 운명 조절용 조성물
WO2020097566A1 (en) 2018-11-08 2020-05-14 Cedars-Sinai Medical Center Use of clazakizumab to desensitize and improve renal transplantation in hla-sensitized patients
CA3121934A1 (en) 2018-12-20 2020-06-25 Cedars-Sinai Medical Center Clazakizumab in the treatment of chronic antibody-mediated rejection of organ transplant
WO2021160887A1 (en) 2020-02-14 2021-08-19 Immunor As Corona virus vaccine
AU2021379816A1 (en) * 2020-11-13 2023-06-22 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising human interleukin 2 variant or derivative thereof and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652636A1 (de) * 1976-11-19 1978-05-24 Hans Uwe Dr Rer Nat Wolf Verfahren zur stabilisierung von proteinen und verwandten verbindungen waehrend ihrer reinigung, isolierung und lagerung
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
WO1985004328A1 (en) * 1984-03-28 1985-10-10 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
DE3583880D1 (de) * 1984-04-09 1991-10-02 Takeda Chemical Industries Ltd Stabile interleukin-2-zusammensetzung.
CA1297003C (en) * 1985-09-20 1992-03-10 Jack H. Nunberg Composition and method for treating animals
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like

Also Published As

Publication number Publication date
EP0268110A1 (de) 1988-05-25
DE3778122D1 (de) 1992-05-14
AU614066B2 (en) 1991-08-22
AU8018187A (en) 1988-04-28
CA1292686C (en) 1991-12-03
JPS63122628A (ja) 1988-05-26
EP0268110B1 (de) 1992-04-08
GR3004479T3 (de) 1993-03-31
IE60890B1 (en) 1994-08-24
IE872844L (en) 1988-04-27
ES2036558T3 (es) 1993-06-01

Similar Documents

Publication Publication Date Title
ATE74512T1 (de) Pharmazeutische zusammensetzungen von rekombinanten interleukin-2 und herstellungsverfahren.
ATE111744T1 (de) Pharmazeutische zusammensetzungen von rekombinantem beta-interferon und herstellungsverfahren.
DK0388220T3 (da) Præparater til vedvarende frigivelse af klorhexidin
ES2132066T3 (es) Procedimiento para la produccion de proteina biologicamente activa (v.g. tfg).
AU590896B2 (en) Improved formulations for recombinant beta-interferon
DK16890D0 (da) Antiviral eller antibakteriel forbindelse og frem gangsmaade til anvendelse heraf
DE3868886D1 (de) Fettsaeure-zusammensetzungen.
DE3681243D1 (de) Stabile formulierung biologisch aktiver proteine zur parenteralen injektion.
DK0693924T3 (da) Fremgangsmåde til (in vivo)-levering af biologiske materialer og sammensætninger, der er egnede dertil
IT1232827B (it) Proteine biologicamente attive, formulazioni che le contengono e metodo per prepararle ed applicarle
SE8404065D0 (sv) Novel biologically active compounds
FR2707638B1 (fr) Nouveaux dérivés d'amino-acides, leurs procédés de préparation et leur application thérapeutique.
ATE85213T1 (de) Einen wirkstoff und ein in wasser quellendes polymer enthaltendes arzneimittel.
DK291390D0 (da) Terapeutiske anvendelser af 2',5'-oligoadenylatderivater
DK516288A (da) Stabilisering af terapeutisk aktive proteiner i farmaceutiske praeparater
DE69228031D1 (de) Ch0ndromodulin-II Protein
FR2605223B1 (fr) Compositions therapeutiques stables a base d' huile vegetale hydrophobe et son procede de preparation
DE3781017D1 (de) Cytotoxische zusammensetzung aus "killer"-zellen.
IT1197892B (it) Composizioni farmaceutiche ad attivita' cicatrizzante
BG60657B2 (en) Human recombinant interleukin-2 muteins

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEFA Change of the company name
EEIH Change in the person of patent owner
EELA Cancelled due to lapse of time